Jane Street Group, LLC Pliant Therapeutics, Inc. Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

A detailed history of Jane Street Group, LLC transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 186,726 shares of PLRX stock, worth $2.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

186,726

Previous 237,498 21.38%

Holding current value

$2.3 Million

Previous $2.55 Million 18.02%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$10.52 - $14.35 $534,121 - $728,578	-50,772 Reduced 21.38%	186,726 $2.09 Million
Q2 2024 Aug 14, 2024	BUY	$10.58 - $15.61 $1.15 Million - $1.7 Million	108,586 Added 84.23%	237,498 $2.55 Million
Q1 2024 May 15, 2024	BUY	$14.14 - $19.59 $562,319 - $779,055	39,768 Added 44.61%	128,912 $1.92 Million
Q4 2023 Feb 14, 2024	BUY	$12.85 - $19.15 $846,879 - $1.26 Million	65,905 Added 283.6%	89,144 $1.61 Million
Q3 2023 Nov 14, 2023	SELL	$14.58 - $20.15 $804,655 - $1.11 Million	-55,189 Reduced 70.37%	23,239 $402,000
Q2 2023 Aug 14, 2023	SELL	$18.12 - $30.56 $2.61 Million - $4.4 Million	-144,102 Reduced 64.76%	78,428 $1.42 Million
Q1 2023 May 15, 2023	BUY	$18.73 - $36.26 $3.34 Million - $6.46 Million	178,237 Added 402.4%	222,530 $5.92 Million
Q4 2022 Feb 14, 2023	BUY	$17.0 - $25.43 $752,981 - $1.13 Million	44,293 New	44,293 $856,000
Q3 2020 Nov 17, 2020	SELL	$21.54 - $29.53 $288,399 - $395,377	-13,389 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$21.3 - $35.26 $285,185 - $472,096	13,389 New	13,389 $435,000

Others Institutions Holding PLRX

# of Institutions

168

Shares Held

63.2M

Call Options Held

245K

Put Options Held

373K

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $600M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Pliant Therapeutics, Inc. Transaction History